Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2025 (2025-12-31): -323.11%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-504.08%
RETURN ON EQUITY (ROE) AVG 3Y
-134.56%
RETURN ON EQUITY (ROE) AVG 5Y
-153.25%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Opus Genetics, Inc.
Market Cap
$365.88M
Return on Equity (ROE)
N/A
TTM Avg
-504.08%
3Y Avg
-134.56%
5Y Avg
-153.25%
Market Cap
$359.35M
Return on Equity (ROE)
-7.66%
TTM Avg
-10.18%
3Y Avg
260.20%
5Y Avg
144.75%
Market Cap
$357.45M
Return on Equity (ROE)
N/A
TTM Avg
-12.63%
3Y Avg
-14.73%
5Y Avg
14.28%
Market Cap
$357.39M
Return on Equity (ROE)
-26.14%
TTM Avg
-53.80%
3Y Avg
-12.25%
5Y Avg
19.21%
Market Cap
$357.11M
Return on Equity (ROE)
-62.56%
TTM Avg
-108.31%
3Y Avg
-79.06%
5Y Avg
-57.33%
Market Cap
$356.88M
Return on Equity (ROE)
N/A
TTM Avg
187.63%
3Y Avg
25.60%
5Y Avg
-9.96%
Market Cap
$356.54M
Return on Equity (ROE)
10.07%
TTM Avg
9.56%
3Y Avg
8.63%
5Y Avg
13.79%
Market Cap
$376.22M
Return on Equity (ROE)
-38.57%
TTM Avg
-80.22%
3Y Avg
-181.01%
5Y Avg
-130.47%
Market Cap
$377.23M
Return on Equity (ROE)
-92.20%
TTM Avg
-58.64%
3Y Avg
-50.24%
5Y Avg
-28.80%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Opus Genetics, Inc. (IRD) | $365.88M | N/A | -504.08% | -134.56% | -153.25% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.35M | -7.66% | -10.18% | 260.20% | 144.75% |
| Embecta Corp. (EMBC)vs › | $357.45M | N/A | -12.63% | -14.73% | 14.28% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $357.39M | -26.14% | -53.80% | -12.25% | 19.21% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $357.11M | -62.56% | -108.31% | -79.06% | -57.33% |
| Ocugen, Inc. (OCGN)vs › | $356.88M | N/A | 187.63% | 25.60% | -9.96% |
| Viemed Healthcare, Inc. (VMD)vs › | $356.54M | 10.07% | 9.56% | 8.63% | 13.79% |
| Canopy Growth Corporation (CGC)vs › | $376.22M | -38.57% | -80.22% | -181.01% | -130.47% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $377.23M | -92.20% | -58.64% | -50.24% | -28.80% |
| YD Bio Limited Ordinary Shares (YDES)vs › | $378.24M | -66.49% | 134.81% | 90.61% | 61.31% |
ROE
N/A
ROA
-115.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -323.11% |
| 2025-06-30 | -333.51% |
| 2024-12-31 | -855.62% |
| 2024-09-30 | -79.28% |
| 2024-06-30 | -34.71% |
| 2024-03-31 | -24.54% |
| 2023-12-31 | -20.01% |
| 2023-09-30 | 57.18% |
| 2023-06-30 | 49.49% |
| 2023-03-31 | 45.31% |
| 2022-12-31 | 38.69% |
| 2022-09-30 | -188.31% |
| 2022-06-30 | -151.18% |
| 2022-03-31 | -140.54% |
| 2021-12-31 | -255.12% |
| 2021-09-30 | -335.80% |
| 2021-06-30 | -292.99% |
| 2021-03-31 | -616.81% |
